Dublin, July 29, 2024 (GLOBE NEWSWIRE) -- The "Prurigo Nodularis: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.
This report provides a data-driven overview of the current and future competitive landscape in PN (Peripheral Neuropathy) therapeutics. In 2024, more than 1.4 million diagnosed prevalent cases of PN are anticipated in the 16 countries covered in the analyst's epidemiology forecast for PN.
Currently, there is only a single disease-modifying innovator therapy available in the market for PN. The PN pipeline comprises 20 molecules, with three drugs in Phase III and nine drugs in Phase II. Over the past 10 years, approximately 34.9% of clinical trial sites for PN were in Europe, followed by 34.4% in Asia-Pacific. Additionally, asset transaction deals were notably prevalent in Europe and North America, reflecting significant activity in these regions.
Key Topics Covered:
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Molecule Type
4.4 Product Profiles and Sales Forecast
5 Pricing and Reimbursement Assessment
5.1 Annual Cost of Therapy
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Mid-to-late-stage Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Mechanism of Action
6.4 Overview by Molecule Type
6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.6 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Overview of Trials by Geography
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/e35j3i
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
